April 28 | 11-11:45AM | ZOOM
What have we learned about the complex disease of obesity? Science has evolved our understanding that it takes more than eat less and move more to achieve weight loss. For people living with obesity, weight loss isn’t the only measure of success in treating obesity. Join us for discussion on April 28th at 11am with the San Francisco Chamber of Commerce President & CEO, Rodney Fong and Ryan Flugge, PharmD from Novo Nordisk to learn about:
- The science of obesity
- The impact of obesity on COVID-19
- The impact of obesity on employers and employee health
- The benefits of weight loss beyond the scale
- Types of tools available to help treat obesity
Novo Nordisk is a global healthcare company with almost 100 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions including obesity, hemophilia and growth disorders. Obesity is a chronic disease that leads to many other weight-related diseases. When it comes to our weight, genetics, biology, and the environment all play a role. We’re committed to improving the lives of people with obesity by collaborating with the community on education and advocacy, increasing access to care, and advancing medical management. Together with our partners, we are changing how the world sees, prevents, and treats obesity.
Ryan Flugge, Medical Account Associate Director at Novo Nordisk. Dr. Flugge has focused on obesity as a chronic disease, he works to educate employers on the disease state, impact on employers, impact on employees, and the current evidence for addressing obesity in the work place. A board certified pharmacotherapy specialist, Dr. Flugge hopes to help identify ways employers can improve outcomes in individuals living with obesity. Dr. Flugge earned his Doctor of Pharmacy degree from the University of Iowa College of Pharmacy and went on to practice at the University of Nebraska Medical Center and the VA before joining Novo Nordisk.